Therapeutic targeting of genomic instability in triple negative breast cancer

Ended Project Grant Awarded Last action

Award ID
HT94252310821
Recipient
Awarding agency
Obligated
$1,050,767

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The $1,050,767 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University Health Network (UHN) to investigate therapeutic targeting of genomic instability in triple negative breast cancer. The research will be conducted at UHN's location in Ottawa, Ontario over a 3-year period from September 2023 to September 2026. This funding supports UHN's ongoing biomedical and clinical research programs, which frequently involve collaboration with top U.S. research institutions to advance medical treatments for military service members and veterans.

Quick answers

Who received award HT94252310821?

HT94252310821 was awarded to University Health Network by Defense Health Agency (Department of Defense) on September 30, 2023.

How much is award HT94252310821 worth?

$1,050,767 has been obligated on HT94252310821.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login